While Gilead (GILD +1.89%) is often thought of as king in the HIV space and is leading the race for successful interferon-free hepatitis C treatment with some astounding cure rates in clinical trials, its recent announcement that it will acquire YM BioSciences (NYSEMKT: YMI) highlights a lesser-known direction for the company: its oncology pipeline. In this video, Motley Fool health care analyst David Williamson discusses what the acquisition means for Gilead and its aspirations in the oncology field.
1 Buyout Bolstering Big Biotech
By Dave Williamson and Brenton Flynn – Dec 14, 2012 at 6:20PM
NASDAQ: GILD
Gilead Sciences
Market Cap
$149B
Today's Change
(1.89%) $2.26
Current Price
$122.05
Price as of November 3, 2025 at 4:00 PM ET
Gilead is renowned for its antiviral drugs, but who knew about its interesting oncology pipeline?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid